Nevirapine
NDC Package 53808-1069-1
Package Information
Nevirapine is indicated for combination antiretroviral treatment of HIV-1 infection in adults and in pediatrics patients 15 days and older [see Clinical Studies (14.1), (14.2)].Additional important information regarding the use of nevirapine for the treatment of HIV-1 infection:•Based on serious and life-threatening hepatotoxicity observed in controlled and uncontrolled trials, nevirapine should not be initiated in adult females with CD4+ cell counts greater than 250 cells/mm3 or in adult males with CD4+ cell counts greater than 400 cells/mm3 unless the benefit outweighs the risk [see Boxed Warning and Warnings and Precautions (5.1)].•The 14-day lead-in period with nevirapine 200 mg daily dosing must be strictly followed; it has been demonstrated to reduce the frequency of rash [see Dosage and Administration (2.4) and Warnings and Precautions (5.2)].•If rash persists beyond the 14-day lead-in period, do not dose escalate to 200 mg twice daily. The 200 mg once-daily dosing regimen should not be continued beyond 28 days, at which point an alternative regimen should be sought. Marketed by State Of Florida Doh Central Pharmacy, this product is identified by NDC 53808-1069 and is authorized under FDA application ANDA203176.
Identification & Billing
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 53808 - State Of Florida Doh Central Pharmacy
- 53808-1069 - Nevirapine
- 53808-1069-1 - 30 TABLET in 1 BLISTER PACK
- 53808-1069 - Nevirapine
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 53808-1069-1 identifies a specific commercial package of 30 tablet in 1 blister pack of Nevirapine, labeled by State Of Florida Doh Central Pharmacy. This is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by State Of Florida Doh Central Pharmacy on November 01, 2014. The current certification is valid through December 31, 2017.
How is this State Of Florida Doh Central Pharmacy product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 53808106901. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.